Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Access event page
Chairpersons: Prof. Ewa Jankowska (Heart Failure Association of the ESC), Prof. John McMurray (ESC),Dr Claudia Kaiser-Albers (MSD), Dr Tomas Andersson (AstraZeneca)
14:00 - 14:10
Introduction – Goals of the CRT and Objectives of the Workshop
Dr C. Kaiser-Albers
SESSION 1 - GUIDELINES 2021 - WHERE DO WE STAND AND WHAT EVIDENCE DO WE STAND ON?
Moderated by Prof. E. Jankowska and Dr T. Andersson
14:10 - 14:25
New Guidelines Presentation
Prof. M. Metra (IT) & Prof. T. McDonagh (UK)
14:25 - 14:35
The Concept of a Universal Definition of Heart Failure
Why and What it Means in Practice
A Joint Venture of HFA/HFSA/JHFS Societies
Prof. B. Bozkurt (US)
14:35 - 14:55
Reflections on the Guidelines and How they are Implemented.How Well Did We Do in the Last Five Years?Examples of Entresto and ICD/CRT
Prof. J. McMurray & Prof. W. Mullens (BE)
14:55 - 15:05
How do We Improve Implementation of Evidence in Practice?Perspectives from Outside Western Europe
Dr O. Chioncel (RO)
15:05 - 15:45
Panel Discussion including Academia, Industry, Payers, Regulatory, Patients
16:55 – 17:05
15:45 - 16:00
16:00 - 17:00
Breakout Sessions : Moderated by Appointed Experts and DiscussantsWhy is the Uptake of Life-Saving Treatments for HF Still Sub-optimal?
17:00 – 17:15
Summary of Pitches - Wrap-up Day 1 - Outlook to Day 2
Prof. E. Jankowska & Dr C. Kaiser-Albers
OPTIMIZING OUTCOMES IN HF
Chaired by Prof. J. Mc Murray and Dr C. Kaiser-Albers
14:00 - 14:15
Summary of Day 1 - Viewpoints from the Breakout SessionsWhat Else are the Hot Topics in HF?
Dr C. Kaiser-Albers & Dr T. Andersson
SESSION 2 - OPTIMIZING OUTCOMES IN HF WHAT ELSE?
Moderated by Prof. J. Mc Murray and Dr C. Kaiser-Albers
14:15 - 14:25
What Do We Mean by “HFpEF” in 2021 and How Should It Be Treated?
Prof. S. Solomon (USA)
Should We Bother About The Treatment Advances: Quality of Life and Functional Capacity?
Prof. A. Coats (UK)
14:35 - 14:45
How do We Measure QoL and Assess Functional Capacity?
Dr L. Hill (UK)
14:45 - 14:55
Patient Perspective: What Matters to Me?(involve patients who have been participating in the discussion on new 2021 HF guidelines.)
Patient representative (tbc)
How Can Regulators and Payers Contribute to Optimize Outcomes? - The EMA Perspective
EMA Speaker (tbc)
15:05 - 15:15
How Can Regulators and Payers Contribute to Optimize Outcomes? - A General Perspective of Payers
Prof. U. Siebert (AT)
15:15 - 15:45
Panel / Moderated Discussion with Panelists and Experts Representing a Geographical Diversity
SESSION 3 - GOING DIGITAL – WILL IT SHAKE UP EVERYTHING?
Moderated by Prof. M. Cowie (tbc)
16:00 - 17:30
Quick Perspectives on:
16:00 - 16:10
Will Digital Tools Help Patients Better Manage Their Disease? Lifestyle, Treatment, Awareness of Disease Fluctuations
Prof. M. Volterrani (IT)
16:10 - 16:20
Can we capture clinical status, activity levels and treatment adherence remotely?
Prof. F. Koehler (DE)
16:20 - 16:30
Education, Implementation, Adherence, Monitoring and Outcomes: The Digital Future of Cardiology
Dr R. Califf (USA)
16:30 - 16:40
Digital Clinical Trials – Patient Enrollment, Monitoring and Collection of Follow-up Data
Prof. Lars Lund (SE)
16:40 - 17:15
Panel Discussion - Could We Have a Common Digital Platform to Deliver Routine Care and Conduct Clinical Trials?
17:15 - 17:30
Key Take-Home Messages / Recommendations in Preparation of the Publication
Our mission: To reduce the burden of cardiovascular disease.
© 2021 European Society of Cardiology. All rights reserved.